Translational Neurodegeneration | Protein kinase CK2α′ as a dual modulator of neuroimmune signaling and synaptic dysfunction in tauopathy

This study reveals the critical role of CK2α′ in tauopathies, offering new experimental design insights for understanding the mechanisms and developing therapeutic strategies for neurodegenerative diseases, particularly emphasizing the therapeutic potential of targeting specific kinase subunits.

 

Literature Overview

The article 'Protein kinase CK2α′ as a dual modulator of neuroimmune signaling and synaptic dysfunction in tauopathy,' published in the journal Translational Neurodegeneration, systematically investigates the function of the catalytic subunit CK2α′ of protein kinase CK2 in tauopathies. By integrating human brain tissue analyses, transgenic mouse models, and cellular experiments, the study uncovers multiple regulatory roles of CK2α′ in tau phosphorylation, neuroinflammation, and synaptic function. Further analyses indicate that upregulation of CK2α′ is closely associated with disease progression, highlighting its potential value as a therapeutic target.

Background Knowledge

Tauopathies are a class of neurodegenerative disorders characterized by abnormal tau protein aggregation, neuroinflammation, and synaptic dysfunction, including Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD). Although tau pathology is considered a core driver of disease progression, no effective therapies are currently available to halt its deterioration. Most existing research has focused on modifications or clearance of tau itself, with insufficient understanding of the specific regulatory mechanisms of upstream kinases. Protein kinase CK2 consists of two catalytic subunits (CK2α and CK2α′) and two regulatory subunits (CK2β). While it has been linked to tau phosphorylation in AD, the distinct functions of the different catalytic subunits remain unclear. In particular, CK2α′ exhibits restricted expression in the brain and possesses unique functions, yet previous studies have often conflated it with CK2α, hindering the development of targeted therapies. This study distinguishes between the functional differences of CK2α and CK2α′, using genetic approaches to investigate whether CK2α′ specifically participates in the regulation of tau pathology, thereby providing a mechanistic basis for developing more precise intervention strategies.

 

 

Research Methods and Experiments

The researchers first analyzed public RNA-seq data and postmortem human brain tissues, discovering that CK2α′ (CSNK2A2) is specifically upregulated in the prefrontal cortex of dementia patients, whereas CK2α (CSNK2A1) shows no significant change. In the PS19 transgenic mouse model, significantly increased levels of CK2α′ protein and mRNA were also observed in the hippocampus, particularly in neurons and microglia. To investigate its function, the authors generated a hybrid PS19 and CK2α′^+/- mouse model, creating CK2α′ haploinsufficiency. Using multidimensional approaches—including immunoblotting, immunohistochemistry, RNA-seq, electrophysiological recordings, and behavioral tests—they systematically evaluated the effects of CK2α′ deficiency on tau pathology, neuroinflammation, synaptic function, and cognitive behavior.

Key Conclusions and Perspectives

• Silencing CK2α′ in N2a cells significantly reduced phosphorylation levels of mutant tau (P301L), as indicated by AT8 signal, whereas silencing CK2α had no such effect, demonstrating that CK2α′ specifically regulates tau phosphorylation and suggesting it as a precise intervention node for targeting tau modifications.
• PS19;CK2α′^+/- mice exhibited significantly reduced phosphorylated tau and total tau burden in the hippocampus and cortex, indicating that CK2α′ haploinsufficiency is sufficient to alleviate tau pathology and supporting its critical role in disease progression.
• CK2α′ haploinsufficiency significantly suppressed microglial activation, pro-inflammatory cytokine release, and synaptic phagocytic activity, showing that CK2α′ contributes to synaptic loss via regulation of neuroimmune signaling pathways, suggesting that targeting CK2α′ could simultaneously improve inflammation and synaptic homeostasis.
• Expression of synaptic-related genes, synaptic density, and long-term potentiation (LTP) were all restored in PS19;CK2α′^+/- mice, indicating that loss of CK2α′ can reverse synaptic dysfunction and providing functional evidence for treating tau-related cognitive decline.
• In Barnes maze testing, CK2α′ haploinsufficiency significantly improved cognitive deficits in PS19 mice, directly demonstrating that targeting CK2α′ yields behavioral benefits and reinforcing its translational value as a therapeutic target.

Research Significance and Prospects

This study is the first to clarify the central role of CK2α′—as opposed to CK2α—in tauopathies, challenging the previous notion of CK2 as a single entity and providing a theoretical foundation for developing subunit-selective inhibitors. Since CK2α′ knockout mice only exhibit male infertility without embryonic lethality, pharmacological inhibition may have a favorable safety profile, making it highly promising for drug development.

From a clinical monitoring perspective, CK2α′ expression levels could serve as a biomarker for disease progression, particularly showing greater specificity in AT8-positive individuals. Additionally, this study highlights the pathogenic role of CK2α′ in microglia, suggesting that neuroimmune crosstalk is a key mechanism, and paving the way for future exploration of cell-type-specific targeting strategies.

In terms of disease modeling, the PS19;CK2α′^+/- mouse provides a more sensitive platform for evaluating anti-tau therapies and can be used to screen compounds that simultaneously improve tau pathology and neuroinflammation. Combined with single-cell sequencing technologies, it will be possible to further dissect the interaction networks of CK2α′ across different brain cell populations.

 

 

Conclusion

This study establishes CK2α′ as a key molecular node linking tau phosphorylation, neuroinflammation, and synaptic dysfunction in tauopathies. Its specific upregulation in patient brain tissues and animal models, along with the significant amelioration of multiple pathological phenotypes upon genetic deletion, indicates that targeting CK2α′ offers multi-faceted therapeutic advantages. Compared to broad inhibition of CK2 kinase activity, selectively targeting the CK2α′ subunit may reduce off-target effects and improve the therapeutic window. This discovery not only deepens our understanding of the pathogenesis of tauopathies but also provides a solid foundation for developing novel disease-modifying therapies. From bench to bedside, CK2α′ holds promise as a key target in future clinical trials, advancing precision medicine for tau-related neurodegenerative diseases and ultimately improving cognitive function and quality of life for patients.

 

Angel White, Peter Gavrilyuk, Persephone Gu, Michael K Lee, and Rocio Gomez-Pastor. Protein kinase CK2α′ as a dual modulator of neuroimmune signaling and synaptic dysfunction in tauopathy. Translational Neurodegeneration.